Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment Seeking Alpha, 12 Feb 2024 Follow Summary Altimmune's stock surged after revealing promising obesity treatment data for pemvidutide, a GLP-1/glucagon…